Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalyst Pharm Inc
(NQ:
CPRX
)
21.24
+0.08 (+0.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
January 18, 2024
With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
3 Biotech Stocks You Can Buy and Hold for the Next Decade
January 15, 2024
These companies are still in the early innings of their growth potential.
Via
The Motley Fool
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024
January 14, 2024
With multiple drugs on the market and revenue ramping up, the sky's the limit.
Via
The Motley Fool
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
January 09, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January
January 08, 2024
Small-cap stocks tend to outperform mid- and large-cap stocks over time and make for an important component of a balanced portfolio.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Why Catalyst Pharmaceuticals Stock Is Trading Lower
January 05, 2024
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning.
Via
Benzinga
Recap: Catalyst Pharmaceuticals Q3 Earnings
November 08, 2023
Via
Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
January 05, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 05, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
January 04, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Amgen Stock Sees Relative Strength Rating Improve To 74
December 29, 2023
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.
Via
Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
December 28, 2023
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.
Via
Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.
Via
Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
December 26, 2023
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.
Via
Investor's Business Daily
Small Caps Are On A Tear Including Speculative Biotechs
December 26, 2023
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation.
Via
Talk Markets
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 21, 2023
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Via
Benzinga
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 18, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 05, 2023
Catalyst Ranked #4 on the List
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
December 04, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
November 16, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 08, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Robinhood Stocks to Buy Right Now
November 05, 2023
The no-cost trading platform's customers have their clear favorites, and they're more mainstream names than you might expect them to be.
Via
The Motley Fool
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 02, 2023
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
October 26, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
October 23, 2023
The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
October 19, 2023
Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalyst's Chairman
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.